University of Missouri - Columbia
Time is running out for the MURR, as it has only 15 years remaining on its current operating license, which was most recently renewed in 2017. American global leadership in nuclear science, and medical isotope technology cannot continue without replacing at least some of the national research reactor assets. Because competing nations are already years ahead and the design, approval construction and commissioning of an expanded research reactor in Columbia will take at least a decade, it is imperative that this effort begin now. A radiopharmaceutical is a drug that consists of a medical radioisotope incorporated into a pharmaceutical molecule. The pharmaceutical molecule conveys the radioisotope to specifically targeted organs, tissues or cells and is used in a clinic or hospital to diagnose and treat disease. In recent years, medical research teams have started to unlock the huge potential of new drug compounds, for both diagnostic and therapeutic applications, and research reactor derived radiopharmaceuticals are now one of the most powerful tools in precision medicine. The now 55-year-old University of Missouri Research Reactor (MURR) is the sole domestic producer of a wide range and large number of medical isotopes and radiopharmaceuticals, which are delivered every week all over America to companies, clinics, and hospitals. Because the most important medical isotopes have half-lives of hours or days, they cannot be stockpiled and they need to be manufactured and distributed every week. Due to these short-half lives it also means relying on foreign production for such treatments would introduce unacceptable transportation and supply chain risks (including potential export restrictions by foreign governments) that could cause delays in patient diagnosis, and/or cancellation of scheduled cancer treatments at major hospitals and clinics all over the country.
Amount Appropriated
$20.0M
Federal Funding Lifecycle
FY2023FFID tracks stages 1–2 — stages 3–5 vary by agency, assistance type, and earmark structure.
Congressional Request
Member submits CPF / CDS
FFIDEnacted
Signed into appropriations law
FFIDAgency Administration
Procurement route not yet determined
SAM.gov / Grants.gov
Opportunity posted publicly
Federal Award
Obligation recorded in USASpending
Evidence Dossier
Federal Award Record
Start a free trial to access this section.
Start free trial →Supporting Evidence
Start a free trial to access this section.
Start free trial →Tier A = Congressional Record or GovInfo. Tier B = committee report or member disclosure. ✓ Verified = exact document match. ~ Verified recipient = entity-level match only.
Enacted — no verified award linked by FFID
This project has been enacted into law. FFID has not yet linked a verified feder…
Start a free trial to see the full commercial context →Project Description
Time is running out for the MURR, as it has only 15 years remaining on its current operating license, which was most recently renewed in 2017. American global leadership in nuclear science, and medical isotope technology cannot continue without replacing at least some of the national research reactor assets. Because competing nations are already years ahead and the design, approval construction and commissioning of an expanded research reactor in Columbia will take at least a decade, it is imperative that this effort begin now. A radiopharmaceutical is a drug that consists of a medical radioisotope incorporated into a pharmaceutical molecule. The pharmaceutical molecule conveys the radioisotope to specifically targeted organs, tissues or cells and is used in a clinic or hospital to diagnose and treat disease. In recent years, medical research teams have started to unlock the huge potential of new drug compounds, for both diagnostic and therapeutic applications, and research reactor derived radiopharmaceuticals are now one of the most powerful tools in precision medicine. The now 55-year-old University of Missouri Research Reactor (MURR) is the sole domestic producer of a wide range and large number of medical isotopes and radiopharmaceuticals, which are delivered every week all over America to companies, clinics, and hospitals. Because the most important medical isotopes have half-lives of hours or days, they cannot be stockpiled and they need to be manufactured and distributed every week. Due to these short-half lives it also means relying on foreign production for such treatments would introduce unacceptable transportation and supply chain risks (including potential export restrictions by foreign governments) that could cause delays in patient diagnosis, and/or cancellation of scheduled cancer treatments at major hospitals and clinics all over the country.
Sponsoring Member
Blaine Luetkemeyer
Representative · MO
Recipient Organization
University of Missouri - Columbia
Want to see more like this?
Start a free 7-day trial for full member intelligence, recipient funding history, opportunity scores, CSV export, and all 112,898 projects.
Data Provenance
- Source
- House Appropriations Committee
- Status
- enacted
- Fiscal Year
- FY2023
- Category
- other unclassified
- Use Case
- research innovation
Found an error in this record?
Report a data errorTechnical & source detail
Embed this project
Share a live status card on your site or article.
<iframe src="https://federalfundingintelligence.com/api/embed/05c4486e-87d1-4624-a907-e6dab96b7035" width="100%" height="190" frameborder="0" style="border:none;border-radius:12px;" title="Federal earmark project"></iframe>Find more like this
Procurement pursuit intelligence
This project has been enacted. FFID maps funded projects to likely downstream procurement channels — including recipient portals, state and local systems, agency programs, and Grants.gov. SAM.gov is monitored, but many CPF/CDS-funded opportunities appear first through recipient or state/local procurement systems.
Principals
University of Missouri - Columbia
Grant recipient
Confirmed from FFID congressional source · website not yet enriched
Inferred procurement pathway
low confidenceLikely procurement owner
unknown
Funding vehicle
grant
Expected channel
Multiple channels — see below
FFID could not determine the procurement channel with high confidence for this agency and category combination. Check the agency program page, Grants.gov, the state procurement portal, and the recipient's own procurement page.
Agency not specifically mapped. Check Grants.gov and the recipient's own procurement portal.
Discovery sources to check manually
Discovery onlyThese portals are not verified matches for this project. SAM.gov and state portals are general search starting points — not confirmed procurement channels.
Not project-specific. Portal coverage varies by state. Check all channels manually.
Procurement signals
Procurement monitoring has not yet run for this project. No conclusion can be drawn about whether an opportunity exists.